FDA and FTC Issue 13 Warning Letters to E liquid Companies for Misleadingly Marketing to Youth; FDA Investigates Underage Use of JUUL Devices The Continuum of Risk FDA issued 30 warning letters to telehealth companies for false and misleading claims about compounded GLP 1 products. This marks the second round of enforcement action since the agency's September crackdown on misleading How to Respond to an FDA Warning Letter? Beyond the Headlines: FDA Warning Letters to GLP 1 Compounders Spencer Fane